AlphaVax

AlphaVax granted vaccine manufacturing patent in U.S.

Published in Medicine and Law Weekly, September 1st, 2006

AlphaVax, a North Carolina-based vaccine company, announced the issuance of U.S. Patent No. 7,078,218 entitled, "Alphavirus particles and methods for preparation."

Claims in this patent cover a broad series of innovative steps that together compose a scaleable process for manufacturing alphavirus replicon particle vaccines (alphavaccines).

The company's alphavaccine platform allows the incorporation of a wide range of antigens to produce vaccines targeting infectious disease, cancer and biodefense threats. AlphaVax has counterparts to this patent pending or issued in 10 major countries and regions throughout the world.

"These key...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2006-09-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry